



8:50-9:00 Welcome Address

Stream 1 Target Identification & Validation



Keynote

Torsten Hoffmann
Senior Vice President Drug
Discovery at Taros Chemicals
Optimization & identification
of novel targets

9:20-9:40

Keynote

Sebastian Nijman

Co-Founder & CSO at Scenic Biotech

Harnessing genetic modifiers

as therapeutic targets

Scenic

Stream 2 Novel Drug Design Approaches



Keynote

Hasane Ratni

Expert Scientist,

Project Team Leader at Roche
Structure-Activity
Relationships in Drug Design

(Roche)

10: 00 - 10: 20 Keynote

Jean-François Ginginger

CSO at Temisis

How regulating the target NFKBIZ/IκΒζ results in very high efficacy in alleviating psoriasis symptoms

temisis

Stream 3 Artificial Intelligence & Machine Learning



10:20-10:40 Keynote

Michael Thormann
CEO at Origenis

Re-imaging Drug Discovery through AI

origenis

10:40 - 11:00

Keynote

Remko van Leeuwen
CEO at Madam Therapeutics

How AI techniques has helped us in shaping our portfolio of antimicrobial compounds

THERAPEUTICS

BEAM
BIO
BEAM
BI

Stream 4 Drug Discovery Innovations & Technologies



Keynote

Thorsten Thormann
VP - Research at LEO Pharma

Targeting protein-protein interactions with small molecule drugs PPIs in immune disease

11: 20 - 11 : 40

Keynote



Co-Founder & CEO at Protinhi Therapeutics

Broad spectrum antivirals as early interventions against viruses posing pandemic threats

Protinhi Therapeut

Treating Disease via Protease Inhil



8:50-9:00 Welcome Address

Stream 5 Medicinal Chemistry & Drug Design



Leif Håkansson **CSO** at Canimguide **Therapeutics**

Structure-Based Drug Design to Overcome Drug Resistance: Challenges and Opportunities



9:20 - 9:40

Keynote




Senior Director, Head Medicinal Chemistry, IMED RIA at AstraZeneca

Developing alternative modalities as the therapeutics approaches in drug discovery

Stream 6 Innovations in HTS & compound profiling









Kamal Azzaoui **CEO/Co-founder** at Saverna Therapeutics Targeting non-coding

functional RNAs



Keynote

Pascal Mayer

CEO at Alphanosos

AI for rapid anti-infective discovery and response to pandemics





Keynote



Scientific Director / Business Developer at SYNCROSOME -Preclinical Efficacy CRO Advances in preclinical approaches to Chagas disease drug discovery

SYNCROSOME IN-DEPTH EFFICACY CHARACTERIZATION CRO

CIphanosos



10:40 - 11:00

Omnicin therapeutics

Auke van Heel

CEO, Co-Founder at Omnicin **Therapeutics**

Increasing the Antimicrobial Activity of Lipid II targeting antibiotics against gram negative pathogens

Stream 8 strategic partnerships & outsourcing



Keynote Keynote



Wolfgang Fecke **Director General**

Tool compounds and drug candidates from the European chemical biology infrastructure **EU-OPENSCREEN**

eu::openscreen



Keynote

Patrizia Anna d'Alessio Founder & CEO at **AISA Therapeutics**

SARS-Cov-2 infection as model for the aging

11:40-1:00 Meeting & Networking

1:00-1:15 Closing Event